1. Indications and Usage
\nSchizophrenia:
\nTreatment of schizophrenia in adults.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Oral Use ONLY.
\nRecommended Dosage:
\nStarting Dose: 4 mg twice daily (8 mg\/day).
\nMaintenance Dose: Adjust based on clinical response; typically 8\u201316 mg\/day.
\nMaximum Dose: 24 mg\/day.
\nCritical Administration Instruction:
\nMUST BE TAKEN AFTER MEALS: Absorption is significantly affected by food. Must be taken after meals to ensure adequate bioavailability. Taking on an empty stomach may result in subtherapeutic levels.
\nDosing Frequency:
\nTypically administered twice daily (BID).
\n3. Mechanism of Action
\nReceptor Profile:
\nBlonanserin is a selective antagonist with high affinity for dopamine D2\/D3 receptors and serotonin 5-HT2A receptors.
\nSelectivity:
\nD2\/D3 Antagonist: Its affinity for D2 receptors is approximately twice that of 5-HT2A receptors. This profile is similar to first-generation antipsychotics but with a lower risk of extrapyramidal symptoms.
\nLow Affinity: It has low affinity for Histamine (H1), Alpha-1 adrenergic, and Muscarinic (M1) receptors.
\nClinical Implication: This selectivity contributes to a favorable profile regarding weight gain, sedation, and orthostatic hypotension compared to other atypical antipsychotics.
\n4. Safety and Warnings
\nIncreased Mortality in Elderly with Dementia (Boxed Warning):
\nElderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
\nSuicidal Thoughts and Behaviors:
\nMonitor for the emergence of suicidal ideation and behavior.
\nNeuroleptic Malignant Syndrome (NMS):
\nA potentially fatal reaction characterized by hyperpyrexia, muscle rigidity, autonomic instability, and elevated CPK.
\nTardive Dyskinesia:
\nRisk of developing abnormal involuntary movements, which may be irreversible.
\nConstipation and Intestinal Obstruction:
\nMay cause severe constipation leading to paralytic ileus.
\n5.Adverse Reactions
\nMost Common:
\nExtrapyramidal Symptoms (EPS): Parkinsonism (tremor, rigidity, bradykinesia), Akathisia (restlessness).
\nHyperprolactinemia: Elevated prolactin levels.
\nInsomnia, Anxiety.
\nNote:
\nUnlike many other atypical antipsychotics, Blonanserin has a lower incidence of somnolence, weight gain, and dry mouth.
\n6.Drug Interactions
\nCYP3A4 Substrate:
\nBlonanserin is primarily metabolized by CYP3A4.
\nStrong CYP3A4 Inhibitors (Contraindicated):
\nContraindicated with potent inhibitors (e.g., ketoconazole, itraconazole, ritonavir) due to significantly increased blonanserin exposure.
\nCYP3A4 Inducers:
\nCaution is advised when used with inducers (e.g., phenytoin, carbamazepine, rifampin) as they may decrease blonanserin efficacy.
\nAdrenaline (Epinephrine):
\nContraindicated. Use with adrenaline may lead to severe hypotension (reversal of epinephrine effect).
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Blonanserin.
\nAvailable Strength: 4 mg tablets.
\nAppearance: White tablets.
\nStorage: Store at 30\u00b0C (86\u00b0F); excursions permitted to 15\u201330\u00b0C (59\u201386\u00b0F).<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u6d1b\u73ca \u00ae(Lonasen\u00ae)
\nGeneric Name: Blonanserin
\nStrength: 4 mg per tablet, 10 tablets per box
\nManufacturer: Sumitomo Dainippon Pharma Co., Ltd. Suzuka Plant
\nSecondary Packaging Site: Sumitomo Pharma (Suzhou) Co., Ltd.
\nMarketing Authorization Holder: Sumitomo Dainippon Pharma Co., Ltd.
\nApproval Date in China: February 21, 2017
\nRegistration Number: HJ20170059 (small package), HJ20170287 (large package)
\nStorage: Store at controlled room temperature (1\u201330\u00b0C), protect from light and moisture, keep tightly sealed. Refer to the package insert for detailed storage instructions.<\/p>\n
Price&Cost:Contact Us now for the best price of Blonanserin \uff08Lonasen\uff09<\/p>\n","protected":false},"featured_media":4074,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27],"product_tag":[],"class_list":["post-4073","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n